-
Mashup Score: 1
In an interview with Targeted Oncology, Ruben Mesa, director, MD, discussed the role of JAK inhibitors in early myelofibrosis and other promising treatment options coming down the pipeline.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Srdan Verstovsek, MD, PhD, shares his take home message from his presentation on accelerated and blastic phase myeloproliferative neoplasms during the first Annual Texas MPM Workshop.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The main development in the field has been the new treatment strategies in accelerated and blastic MPNs where we now have the ability to use medications in different ways for different clinical situations, says Dr. Verstovsek. https://t.co/V8ziv9kTr9 #mpnsm #TxMPN2020
-
-
Mashup Score: 1
During the 1st Annual Texas MPM Workshop, Aaron Gerds, MD, MS presented on the ruxolitinib in the present and future, as well as the possibilities for moving beyond the JAK-STAT pathway.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“As a result [of these trials] JAK inhibitors have become a major part of our treatment algorithm. Whether it's low-risk disease, intermediate-risk disease, or high-risk disease, JAK inhibitors pop up all over the place and are the mainstay..." https://t.co/Q5ONAWNP2P #TxMPN2020
-
-
Mashup Score: 0
Patients considered to have early myelofibrosis are a heterogeneous group for whom disease risk, best treatment strategies, and the probability of mortality are best determined individually by looking at patient’s clinical characteristics and molecular markers together.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“Earlier patients all have areas in which they might benefit [from therapy], but as is natural, that evolution occurs as we develop more efficacy and safety data for these medications…" said Dr. Mesa at #TxMPN2020 https://t.co/4VxoEbgT4o #MPNsm
-
-
Mashup Score: 0
Patients considered to have early myelofibrosis are a heterogeneous group for whom disease risk, best treatment strategies, and the probability of mortality are best determined individually by looking at patient’s clinical characteristics and molecular markers together.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Concluding the discussion, Mesa said understanding why patients progress will be important in the selection of novel therapies for patients with early myelofibrosis. https://t.co/4VxoEbgT4o #mpnsm #TxMPN2020
-
-
Mashup Score: 0
During the 1st Annual Texas MPM Workshop, Aaron Gerds, MD, MS presented on the ruxolitinib in the present and future, as well as the possibilities for moving beyond the JAK-STAT pathway.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In MPNs, ruxolitinib has been evaluated as the experimental drug in multiple randomized clinical trials and has shown benefit, but with the emergence of novel agents, its place in the treatment landscape is undergoing further evaluation. https://t.co/Q5ONAWNP2P #mpnsm #TxMPN2020
-
-
Mashup Score: 2
International interactive virtual workshop on the biology and therapy of Myeloproliferative Neoplasms co-led by Dr. Ruben Mesa (Mays Cancer Center at UT
Source: SymplurCategories: Hem/Oncs, Latest HeadlinesTweet-
What a meeting!! Thanks 🙏 for joining us at the first ever #TxMPN2020 || Top Influencers of #TxMPN2020 👉 @mpdrc @doctorpemm @VJHemOnc @PedsHemeDoc @LeukemiaMDA @AaronGerds @harrisoncn1 @jjkiladjian @Vikas_Gupta_1 @UTHealthSAMDA https://t.co/E4C6NTdOmH via @symplur #MPNSM
-
-
Mashup Score: 0Texas Virtual MPN Workshop | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways - 4 year(s) ago
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out our coverage from the first annual #TxMPN2020 Texas Virtual MPN Workshop: https://t.co/UBTuesk95Y https://t.co/iKZhZuRaUp
-
-
Mashup Score: 1
In an interview with Targeted Oncology, Ruben Mesa, director, MD, discussed the role of JAK inhibitors in early myelofibrosis and other promising treatment options coming down the pipeline.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Mesa @mpdrc spoke with us on his presentation at #TxMPN2020, on the role of JAK inhibitors in early myelofibrosis and other promising treatment options coming down the pipeline. https://t.co/wKLfSDUDxI #mpnsm
-
-
Mashup Score: 2Texas MPN Workshop 2020 | VJHemOnc - 4 year(s) ago
Skip to contentAboutEditorial BoardExpert indexCookie PolicyTerms of UsePrivacy PolicyEditorial policySign upContactNewsletters Visit Home (current) Diseases CLL Multiple Myeloma Lymphoma MDS Amyloidosis MPNs AML CML ALL View all Diseases Topics Transplantation Measurable Residual Disease Real-World Data CAR-T & Cellular Therapy Immuno-Oncology Diagnosis…
Source: VJHemOncCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @VJHemOnc: For those who missed the presentations at #TxMPN2020... See @VJHemOnc 👉https://t.co/WMUXyOXYkf 👈 for exclusive #MPN updates…
-
"My key takeaway is to be incredibly hopeful for having such a robust set of therapies...many of which are active, credible, and we might have, 2 years from now, multiple approved agents that might have a variety of different pathways..." https://t.co/wKLfSDUDxI #mpnsm #TxMPN2020